All In Biotech

BLA 019959 · Novo Nordisk INC

Novolin N

Insulin Susp Isophane Recombinant Human · Injection · Insulin

Last checked: Nov 20, 2026Latest source record: Nov 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Jul 1, 1991

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4

0 Phase 3, 0 recruiting

FAERS reports

6,504

4,443 serious, 593 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 23, 2022.

NOVOLIN N is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. NOVOLIN N is an intermediate-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )

Mechanism: The primary activity of insulin, including NOVOLIN N is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 1, 1991 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • NOVOLIN N · INSULIN SUSP ISOPHANE RECOMBINANT HUMAN 100 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Susp Isophane Recombinant Human" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,003
  • blood glucose decreased365
  • drug ineffective362
  • nausea332
  • dyspnoea281
  • diarrhoea274
  • dizziness234
  • fatigue231
  • death227
  • hypoglycaemia225
  • fall213
  • malaise208

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200491
2005150
2006232
2007144
2008191
2009246
2010181
2011144
2012207
2013242
2014330
2015769
2016537
2017568
2018609
2019569
2020286
2021246
2022179
2023138
2024166
2025193
202686

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Novolin N (Insulin NPh Human Isophane)

2024 spending

$14.0M

Beneficiaries

25,782

98,923 claims

Per beneficiary

$543

$4.44 per unit

View as table
YearSpending
2020$70,350,615
2021$63,435,398
2022$59,244,051
2023$53,437,662
2024$13,990,145

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.